Mercados españoles cerrados en 2 hrs 46 min

AbbVie Inc. (ABBV)

NYSE - NYSE Precio demorado. Divisa en USD
Añadir a la lista de favoritos
164,66+0,41 (+0,25%)
Al cierre: 04:00PM EDT
164,98 +0,32 (+0,19%)
Antes de la apertura: 08:42AM EDT

AbbVie Inc.

1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com

Sector(es)Healthcare
SectorDrug Manufacturers - General
Empleados a tiempo completo50.000

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Richard A. GonzalezChairman & CEO7,19MN/A1954
Mr. Robert A. MichaelPresident & COO4,62MN/A1970
Mr. Scott T. ReentsExecutive VP & CFO3,13MN/A1968
Dr. Azita Saleki-Gerhardt Ph.D.Executive VP & COO3,51M5,25M1963
Mr. Jeffrey Ryan StewartExecutive VP & Chief Commercial Officer4,32M2,13M1969
Dr. Thomas J. Hudson M.D.Senior VP & Chief Scientific Officer of Global ResearchN/AN/A1962
Ms. Elizabeth SheaSenior Vice President of Investor RelationsN/AN/AN/A
Mr. Perry C. SiatisExecutive VP, General Counsel & SecretaryN/AN/A1975
Mr. Sanjay NarayanSenior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic LegalN/AN/AN/A
Mr. Timothy J. RichmondExecutive VP & Chief Human Resources Officer1,12MN/A1966
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Gobierno corporativo

El ISS Governance QualityScore de AbbVie Inc., a día 1 de abril de 2024, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 5; Derechos de los accionistas: 9; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.